Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma  

作　　者：Shinji Itoh Masafumi Ikeda 

机构地区：[1]Department of Surgery and Science,Graduate School of Medical Sciences,Kyushu University,Fukuoka,Japan [2]Department of Hepatobiliary and Pancreatic Oncology,National Cancer Center Hospital East,Kashiwa,Japan

出　　处：《Hepatobiliary Surgery and Nutrition》2022年第6期876-878,共3页肝胆外科与营养（英文）

摘　　要：Atezolizumab plus bevacizumab is currently the main choice of first-line treatment for unresectable hepatocellular carcinoma(HCC),which has been proven superior to sorafenib for overall survival(OS)and progression-free survival(PFS)in the phase III IMbrave150 trial(1).Up-data analysis from IMbrave150 showed that the median OS was 19.2 months for atezolizumab plus bevacizumab and 13.4 months for sorafenib[hazard ratio(HR)=0.66;95%confidence interval(CI):0.52-0.85;P=0.0009],and the median PFS was 6.9 and 4.3 months(HR=0.65;95%CI:0.53-0.81;P=0.0001)(2).

关 键 词：BEVACIZUMAB HEPATOCELLULAR PATIENTS 

分 类 号：R735.7[医药卫生—肿瘤]